Cynosure® Announces PicoSure® Is FDA-Cleared To Treat Acne Scars The World's Most Advanced Laser Technology for Tattoo Removal and Benign Pigmented Lesions Is Now FDA-Cleared To Treat Acne Scars
WESTFORD, Mass., July 29, 2014 /PRNewswire/ -- With acne as the most common skin condition affecting more than 60 million Americans today, it is no surprise that 20 million people have severe enough acne to cause scarring (33 percent of sufferers). Cynosure, the leader in aesthetic lasers, announced today that PicoSure is the first and only picosecond laser now FDA-cleared to treat acne scars.
"We are thrilled to announce that PicoSure, the world's most advanced laser technology for tattoo removal and benign pigmented lesions, has now received FDA-clearance to treat acne scars," says Cynosure President and CEO Michael Davin "Our dedication to clinical research offers patients incomparable treatment options and the highest satisfaction to-date. With new treatments continuing to emerge, PicoSure's latest indication is another milestone and evidence of Cynosure's commitment to the evolution of picosecond laser technology."
New results from PicoSure clinical studies show a dramatic improvement in the appearance of acne scars in as little as three treatments, giving sufferers a reason to celebrate. "Acne scarring can happen even without picking; acne lesions, particularly cysts, can lead to scarring due to the intense, collagen-damaging skin inflammation," says Dr. Emil Tanghetti of The Center for Dermatology and Laser Surgery.
In clinical studies, 77% of patients achieved greater than 50% improvement as graded by the physician:
- PicoSure received 97% physician satisfaction rate at the one month follow up appointment and increased to 100% at the three month follow up.
- PicoSure received 76% patient satisfaction rate at the one month follow up appointment and increased to 86% patient satisfaction rate at the three month follow up.
"PicoSure's PressureWave™ technology gently delivers ultra-short pulses of energy in trillionths of a second resulting in increased density and length of elastin fibers and increased collagen deposition," says Dr. Jeremy Brauer of Laser & Skin Surgery Center of New York. Based on results from Cynosure's clinical study, these are very positive signs to restoring normal skin elasticity in the scar tissue and thus reducing the appearance of the scar.
About Cynosure, Inc.:
Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com.
SOURCE Cynosure, Inc.